Kornimate/medical-research-clean huggingface dataset:
treatment for patients with chronic post-concussion symptoms

Conditions: Mild Traumatic Brain Injury; Concussion Post Syndrome

Summary: the current project will examine the effect of a brief psychological intervention on post-concussion symptoms, neurocognitive function, cerebral blood flow (cbf), and psychophysiological and salivary cortisol markers of autonomic nervous system (ans) in a sample of 20 participants between 13-25 years of age who experience long-term post-concussive (pc) symptoms 2-9 months post-injury as well as 20 age- and sex-matched controls (non-injured) participants to provide normative data on all the above measures except for concussive symptoms.

participants with concussion will participate in six, home-based interventions designed to treat cognitive-behavioral factors that are maintaining their symptoms. the investigators hypothesize that the prolonged pc symptoms are in part due to disruption of autonomic nervous system function post-injury as well as exacerbation by the psychological response to the injury. this hypothesis is based on evidence showing that pc symptoms, including headache, fatigue, dizziness, and heightened anxiety overlap with upregulated sympathetic activity and elevated levels of salivary cortisol. there is evidence linking cognitive-behavioral factors (e.g., catastrophizing) to prolonged symptoms of autonomic overactivation after injury (e.g., anxiety, pain, etc.). the participants are taught shallow breathing techniques to normalize parasympathetic activity and provide cognitive-behavioral treatment to reduce psychological reactions to the injury that exacerbate the autonomic disruption and prolong recovery.

Eligibility criteria:
inclusion criteria for patients: * between the ages of 13-25 * diagnosed with a concussion or mild traumatic brain injury by a physician * currently experiencing post-concussive symptoms for at least two months after their injury but no longer than 9 months. * fluent english speaker exclusion criteria: * history of/or comorbid neurological conditions that might affect performance (including history of stroke, seizure disorder, moderate to severe traumatic brain injury, anoxia) * severe cardiovascular conditions. * history of psychosis and current substance abuse or dependence. * current severe symptoms of depression and/or anxiety. additional exclusion criteria for controls: \* no history of concussion in the past year.

Keywords: post-concussion syndrome mild traumatic brain injury autonomic dysfunction concussion capnometry-assisted respiratory training cognitive behavioral therapy
an expanded access study to assess brensocatib for participants with non-cystic fibrosis bronchiectasis

Conditions: Non-Cystic Fibrosis Bronchiectasis

Summary: the purpose of this study is to allow early access to brensocatib for participants with non-cystic fibrosis bronchiectasis (ncfbe) who have successfully completed the ins1007301 aspen clinical trial.

participants will receive brensocatib 10 mg, oral tablets, once daily.

Eligibility criteria:
inclusion criteria: * participant had agreed to provide their informed consent to participate per local requirements. * participant had successfully completed clinical trial ins 1007-301 aspen, including the end of study visit 12 prior to receiving treatment. * requests for post-trial access for brensocatib had come from aspen investigator. * had received brensocatib treatment. exclusion criteria: * participant had experienced a serious adverse event deemed to be related to brensocatib during the study and required permanent participant is continuation. * the participant is immunocompromised or chronically treated with any investigational or commercialized immunomodulatory agent that is directed to any component of the adaptive or innate immune systems. note: the use of any immunomodulatory agents (including but not limited to: bortezomib, ixazomib, thalidomide, cyclophosphamide, mycophenolate, janus kinase inhibitors, ifn-γ, and azathioprine) is prohibited during the program. * the participant had undergone continuous use of high dose non-steroidal anti-inflammatory drugs. * the participant had undergone chronic use of systemic steroids for any chronic condition, except steroids with topical anti-inflammatory activities (ie, oral budesonide). * participant had planned to receive live attenuated vaccines during the program (treatment must be postponed until 4 weeks after the last dose of drug). * participant had planned to use investigational drugs.

Keywords: cathepsin g ckd-epi ncfbe
causes of fuo in infants and children

Conditions: Fever of Unknown Origin

Summary: definition: fever \< 38˚c for which the cause could not be identified, documented by a health care provider after 3w.evaluation as an outpatient \[or after 1w. evaluation in the hospital\]. most cases, however, do not have fever alone, but fuo results from atypical presentation of common diseases. on the other hand fuo lasting longer than 6mo is uncommon in children \& suggests granulomatous, autoimmune or auto inflammatory diseases

fever of unknown origin (fuo) is a relatively common pediatric complaint. the time of fuo generally ranges from 10 to 21 days. generally the fever should be greater than 38.3 ˚c for at least 10 days with no evident source after initial outpatient or inpatient workup. a broad range of illnesses are known to cause fuo, including infectious, autoimmune and oncologic etiologies. definitive diagnosis of fuo can be challenging, with many cases resolving spontaneously without a diagnosis. there is currently no standardized diagnostic approach for working up fuo. the general direction of the workup often depends on the patient's presentation, symptoms, and environmental exposures. it is generally accepted that a complete history and physical examination as well as basic laboratory tests, and empiric antibiotic therapy are initial steps in the workup of fuo. with no advanced resources available, radiographs such as chest x-rays and abdominal ultrasonography as well as simple tests e.g. esr are commonly performed looking for infectious and malignant sources of fuo. if the diagnosis is still obscure laboratory tests for auto immune antibodies or specific infectious agents, are additional logical steps if the diagnosis remains in question. unlike adult studies, the categorical distribution of diagnosis of the causes of fuo in pediatrics has not changed in recent decades (nield\&kamat , 2018) \[1\]. additional studies are needed to improve the recognition of causes of prolonged fever in children. so that fuo is not a single specific medical disorder but may be a potential manifestation of several diseases and disorders. the initial approach to fuo is suggested to be determination of the causes of prolonged fever in each of the body systems, as suggested by the presenting complaint. for instance in the respiratory system in developing countries tuberculosis (tb) must be searched for in the first place. similarly protein energy malnutrition (pem), and vitamin d deficiency rickets must be also thought of as a cause of recurrent / chronic chest infection leading to fuo. in the gastrointestinal system persistant/ recurrent diarrhea must be searched for. in the developing countries, urinary tract infection, typhoid fever and viral hepatitis constitute other hidden causes of fuo. collagen diseases, auto inflammatory diseases as well as immune deficiency diseases and auto immune disorders must be searched for as causes of fuo.

Eligibility criteria:
inclusion criteria: * all fuo cases admitted to auch during one year of the study. exclusion criteria: * cases of hiv
his bundle pacing versus right ventricular pacing

Conditions: Pacing-Induced Cardiomyopathy

Summary: this study will randomize cross-over periods of 6 months of right ventricular pacing and his bundle pacing in patients with baseline left ventricular ejection fraction (lvef)\>40%. the primary outcome measure is lvef.

monocentric, randomized, double-blind comparative crossover clinical study. patients with a standard pacing indication with \>20% ventricular pacing, with a baseline lvef \>40%, implanted with a functioning his bundle lead and a backup right ventricular lead, will be randomized to 6-months periods of right ventricular pacing and of his bundle pacing. the primary outcome is lvef assessed by gated equilibrium radionuclide angiography. secondary outcomes are diastolic function, new york heart association (nyha) functional class, quality of life, 6-minute walk test, heart failure hospitalisations and device electrical parameters.

Eligibility criteria:
inclusion criteria: * baseline lvef\>40% * standard pacing indication with \>20% vp * functional his bundle lead with confirmed his capture * functional right ventricular lead with myocardial capture exclusion criteria: * unable to sign an informed consent form

Keywords: his bundle pacing right ventricular pacing left ventricular systolic function
phase 2 clinical trial of gh001 in postpartum depression

Conditions: Postpartum Depression; Postnatal Depression

Summary: this study is a multicenter, open-label, single-arm phase 2 clinical trial. approximately 15 female participants with clinically diagnosed postpartum depression (ppd) will be included in this study. the participants will receive an individualized dosing regimen (idr) with at least one and up to three doses of gh001 administered within a single day.


Eligibility criteria:
inclusion criteria: * is female and in the age range between 18 and 45 years (inclusive) at screening. * has a body mass index (bmi) in the range of 18.5 and 35 kg/m2 (inclusive) at screening. * meets the trial criteria for ppd as assessed by a trial psychiatrist or registered clinical psychologist. exclusion criteria: * has one or more first or second degree relatives with a current or prior diagnosis of bipolar disorder, psychotic disorder or other mood disorder (including mdd) with psychotic features. * current pregnancy resulting in termination, still-birth, pre-term delivery (before week complete gestational week 37), need for intensive care therapy of mother or child, or adoption of child away from patient. * has taken prohibited medication or prohibited dietary supplements within the specified timeframe prior to dosing. * has previously experienced a significant adverse reaction to a hallucinogenic or psychedelic drug according to the investigator's judgment. * has a clinically significant abnormality in physical examination, vital signs, ecg, or clinical laboratory parameters which renders the patient unsuitable for the trial according to the investigator's judgment. * patient who has a positive pregnancy test at screening or on the pretest day, is pregnant, or plans to become pregnant during the course of the trial and up to 90 days after gh001 dosing.

Keywords: depression postpartum depression 5-methoxy-n,n-dimethyltryptamine 5-meo-dmt mebufotenin postnatal depression
eat my abcs project

Conditions: Nutrition, Healthy; Obesity, Childhood

Summary: evaluate the effects of the "eat my abcs" program on improving head start preschoolers' eating behavior and anthropometric properties (bmi, percent body fat).

the 14-week, community-led, program, aimed to establish lifelong healthy eating habits among vulnerable low-income preschoolers living in rural michigan, includes three main components: (1) "eat my abcs" child curriculum, (2) child fruit/vegetable letters to parents, and (3) program cookbook. "eat my abcs" child curriculum. head start teachers, along with teacher assistants/aids, will independently teach the age appropriate "eat my abcs" curriculum per week, for a total of 14 weeks. the "eat my abcs" curriculum follows the alphabet theme and incorporates the five senses into learning (hear fruit and vegetable information, see the color, feel the texture, smell the scent, and taste the flavor). each week includes two sessions: 1) healthy eating learning on one fruit and one vegetable by incorporating school readiness knowledge on numbers, shapes, colors, and alphabets; and 2) food taste-testing activities to expose children to one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty. child letter to parents. every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home. program cookbook. the investigators have developed a targeted program cookbook for low-income families to overcome their limited cooking skills, busy schedules, and tight family budget. the program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets; and these recipes are culturally appropriate with a variety of choices such as american, italian, mexican, and asian cuisines. in the cookbook, the investigators also promote slow /pressure-cooking recipes as using a slow or pressure cooker to prepare easy but healthy meals is an effective way to overcome low-income parent barriers of lack of time and cooking skills. in addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home.

Eligibility criteria:
inclusion criteria: * any preschoolers aged 3-5 years old from the participating daycare classrooms. * having parental consent. exclusion criteria: * none
comparable study of different radiation dose in esophageal carcinoma

Conditions: Esophageal Carcinoma

Summary: radiation therapy plus concurrent chemotherapy is now the standard therapy for patients with localized carcinoma of the esophagus selected for nonsurgical treatment. the standard radiation dose is 50-50.4gy/1.8-2.0gy/f.all of this were based on 2d radiation technology. entering new century, 3d-crt or imrt has used on esophageal cancer. in china,the recommend radiation dose of concurrent chemoradiation was 60gy. the study is a clinical phase iii, randomized trial to compare the different radiation dose(60gy vs 50gy) of concurrent chemoradiation using 3d-crt or imrt in patients with unresectable esophageal carcinoma.


Eligibility criteria:
inclusion criteria: * histological or cytologic diagnosis of esophageal carcinoma * ecog performance status 0-1 * age:18-70 years * joined the study voluntarily and signed informed consent form * patients must not have received any prior anticancer therapy * unresectable disease, or refuse surgery.stage ⅰ-ⅳa（ajcc 2009） * target lesions can be measured according to recist criteria * no serious system dysfunction and immuno-deficiency, adequate organ function including the following: hemoglobin ≥9 g/dl, wbc≥3x109/l, neutrophils (anc )≥1.5x109/l, platelet count ≥100x 109/l, tbil\<1.5 x uln, alt and ast ≦ 2.5 x uln, creatinine ≦ 1.5 x uln * use of an effective contraceptive for adults to prevent pregnancy * life expectancy of more than 3 months exclusion criteria: * multiple carcinomas of the esophagus, * biopsy-proven invasion of the tracheobronchial tree or tracheoesophageal fistula, * metastatic disease (m1), * a primary tumor that extended to within 2 cm of the gastroesophageal junction, * prior chemotherapy, prior thoracic radiation, surgical resection of the primary tumor, * concurrent pregnancy or lactation, history of a second malignancy other than nonmelanoma skin cancer

Keywords: esophageal carcinoma chemoradiation radiation dose
coronavirus infection in primary or secondary immunosuppressed children and adults.

Conditions: Immune Suppression; Immune Deficiency; Infection; COVID; Children, Adult

Summary: a weekly questionnaire is sent to patients and parents of patients who are vulnerable for infections. possible symptoms of covid19 are asked for and use of healthcare services and testing for covid19. weekly reports are being send to the national institutions to update advice given to this group.

this study is designed to allow immunosuppressed children, their parents or adult patients to self-record their experiences of covid-19 and other viral respiratory illnesses. patients, parents and of immunosuppressed patients and patients aged 16-17 yrs will be provided with online information and asked to fill in online questionnaires at baseline and weekly thereafter. information collected includes medication, symptoms, contact with health care providers, test results and impact on daily activities. data will be collected and analysed weekly to be able to monitor any potential risk factors for severe disease. this study is complementary to, and not overlapping with, the global isaric world health organisation protocol that will be studying covid-19 cases admitted to all national health service (nhs) trusts, including all children.

Eligibility criteria:
inclusion criteria: * children part: parent of immunosuppressed patient aged \<16 years or immunosuppressed patient aged 16-17 years * adult part: immunosuppressed patient aged \>17 years * family or themselves able to complete the questionnaire which will be in english (due to current resources available translation will not be possible) * reliable access to the internet exclusion criteria: * unable to understand english
metformin with standard taxotere and prednisone in the treatment of castration resistant prostate cancer

Conditions: Prostate Cancer

Summary: this study is being conducted to determine the effectiveness of standard 3 weekly treatments using docetaxel and prednisone with metformin in patients with castration-resistant metastatic prostate cancer. it is also being conducted to determine the levels of toxicity of metformin when added to every 3 weekly docetaxel treatments in patients with endocrine resistent, metastatic prostate cancer.

this is a single-arm, non-randomized phase ii trial of docetaxel given every 3 weeks with metformin twice daily and prednisone twice daily. the study duration of this trial is open ended. the patient would take the metformin only for as long as they are treated with docetaxel.

Eligibility criteria:
inclusion criteria: * all patients, 18 of age or older, with hormone refractory prostate cancer are eligible. * patients must have a life expectancy of at least 12 weeks. * patients must have a zubrod performance status of 0-2. * patients must sign an informed consent. * patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of \> 1,500 or cells/mm3 and platelet count \>100,000/mm3 and absence of a regular red blood cell transfusion requirement. * patients should have adequate hepatic function with a total bilirubin \< 2 mg/dl and sgot or sgpt \< two times the upper limit of normal, and adequate renal function as defined by a serum creatinine \< 1.5 x upper limit of normal. * patients must have pathologically confirmed prostate cancer with psa increasing despite androgen deprivation therapy. * diabetic patients on therapy with metformin are eligible provided that their metformin dose is at least 850mg twice daily. exclusion criteria: * patients with symptomatic brain metastases are excluded from this study. * patients on insulin are not eligible. * patients may receive no other concurrent chemotherapy or radiation therapy during this trial. * patients with severe medical problems such as uncontrolled diabetes mellitus, cardiovascular disease, and congestive heart failure defined as new york heart association class iii or iv, hepatic dysfunction, or active infections are not eligible for this trial.

Keywords: prostate castration resistant hormone resistant crpc
effects of benaglutide on weight and gut microbiota in obese patients

Conditions: Obesity

Summary: the purpose of this studay is to evaluate the effects of benaglutide on the treatment of subjects with obesity.


Eligibility criteria:
inclusion criteria: 1. patients aged 18 to 65 years (to the date of screening)； 2. the newly diagnosed obese patients (bmi greater than 28 kg/m2) or abdominal obesity (male waist circumference is greater than 90cm, female waist is greater than 85cm). 3. nearly a month have not used weight-related drugs,including various weight-loss drugs,glp-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid drugs,etc;or recently used weight-related drugs but the stable dose was more than 1 month,and the drug dose remained constant or decreased during the trial. 4. weight stable for more than 3 months (weight fluctuations \<5%). exclusion criteria: 1. pregnant female. 2. secondary diseases caused by other diseases: including hypothyroidism, increased cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of drug-induced obesity, and others. 3. severe cardiovascular and cerebrovascular diseases (heart failure, myocardial infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or pulmonary insufficiency, renal failure, severe hepatitis. 4. combined with acute complications of diabetes such as ketoacidosis, lactic acidosis, hyperosmolar state of diabetes. 5. nearly a month had surgery, trauma, infection and so on. 6. limb deformity incomplete, difficult to accurately determine the height, weight and other physical indicators. 7. poor medication compliance or serious side effects (severe rash, syncope, etc.).
central nervous system(cns) efficacy of dacomitinib

Conditions: Non Small Cell Lung Cancer; Brain Metastases

Summary: this is a single-arm, phase ii study of dacomitinib in advanced egfr-mutant nsclc patients who have non-irradiated brain metastasis.


Eligibility criteria:
inclusion criteria: * biopsy proven recurrent or metastatic nsclc (adenocarcinoma) with major egfr mutation (exon 19 deletion or leu858arg mutation without the thr790met) * no prior systemic treatment of advanced nsclc (neoadjuvant or adjuvant chemotherapy are allowed, without limitation on its treatment timing) * age ≥20 years * eastern cooperative oncology group (ecog) performance status of 0 to 1 * had at least one measurable intracranial lesion as ≥ 5mm in the longest diameter by magnetic resonance imaging (mri) (≥ 5mm by thin section (1.2mm) of brain mri image, ≥ 10mm by less thin section(2.5mm) brain mri ), which checked within 4 weeks before enrollment. if mri slice thickness is not appropriate, we need to recheck brain mri * number of brain metastasis =\>5 * adequate organ function * female subjects must either be of non-reproductive potential * subject is willing and able to comply with the protocol * signed written informed consent exclusion criteria: * severe symptomatic brain metastasis, needing urgent control with radiotherapy or high dose steroid: the definition of high dose steroid is the equivalent dose of dexamethasone 10 mg or higher per day (mild symptoms controlled with low dose of steroid can be enrolled) * with leptomeningeal seeding * exposure to egfr-tkis or other egfr targeting agents at any time in either neoadjuvant or adjuvant setting * local treatment (stereotatic radiosurgery or whole brain radiotherapy) for brain metastases * uncontrolled systemic illness including uncontrolled hypertension, active bleeding, or active infection. * past medical history of interstitial lung disease, drug induced interstitial lung disease, radiation pneumonitis which required steroid treatment * has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.